Arcutis Announces Appointment of Terrie Curran to Board of Directors
November 04 2020 - 4:05PM
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a medical dermatology
company developing innovative treatments for patients with
immune-mediated dermatological diseases and conditions, today
announced that Terrie Curran has been appointed to the Arcutis
Board of Directors effective Nov. 2, 2020, and that Alexander Asam,
Ph.D. has decided to step down from the Board.
“We are tremendously grateful for Alexander’s
contributions to Arcutis,” commented Patrick Heron, Chairman of the
Arcutis Board of Directors. “His thoughtful counsel and leadership
were instrumental in our recent progress, particularly our two
recent very successful public financings. While we will miss his
guidance, we wish him well in his future endeavors.”
“We are absolutely delighted to welcome Terrie
to the Arcutis Board,” said Frank Watanabe, Arcutis’ President and
Chief Executive Officer. “She is an exceptionally talented
biopharmaceutical executive with over 20 years of industry
experience in product commercialization. With her extensive
experience launching and successfully commercializing innovative
products in the dermatology segment, she is uniquely positioned to
help Arcutis in its next stage of development, particularly in
light of the upcoming data from our pivotal Phase 3 trials and
potential NDA submission next year.”
“I am delighted to join the Arcutis board at
this exciting time,” said Terrie Curran. “The Company’s lead
product candidate, topical roflumilast, has the potential to become
the standard of care for plaque psoriasis, atopic dermatitis, scalp
psoriasis, and seborrheic dermatitis. I look forward to
contributing my expertise, specifically with commercialization
planning and execution, to help them build a leading dermatology
company.”
Ms. Curran is CEO and President at Phathom
Pharmaceuticals (Nasdaq: PHAT), a late clinical-stage
biopharmaceutical company focused on developing and commercializing
new treatments for gastrointestinal diseases. Prior to this, she
was the former President, Global Inflammation and Immunology
(I&I) Franchise and member of the Executive Committee at
Celgene. She joined Celgene in 2013 as the U.S. Commercial Head of
the I&I Franchise and built the capabilities and recruited the
teams that executed the successful launch of OTEZLA® for
moderate-to-severe plaque psoriasis. Prior to joining Celgene, she
served as Senior Vice President and General Manager, Global Women’s
Health at Merck & Co. Ms. Curran holds graduate and bachelor’s
degrees from the University of Technology Sydney.
About Arcutis - Bioscience,
applied to the skin.Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is
a medical dermatology company developing innovative treatments for
patients with immune-mediated dermatological diseases and
conditions. The Company is leveraging recent advances in immunology
and inflammation to develop differentiated therapies against
biologically validated targets to solve persistent treatment
challenges in serious diseases of the skin. Arcutis’ robust
pipeline includes four novel drug candidates currently in
development for a range of inflammatory dermatological conditions.
The Company’s lead product candidate, topical roflumilast, has the
potential to become the standard of care for plaque psoriasis,
atopic dermatitis, scalp psoriasis, and seborrheic dermatitis. For
more information, visit www.arcutis.com or follow the company on
LinkedIn and Twitter.
Forward Looking StatementsThis press release
contains "forward-looking" statements, including, among others,
statements regarding data from the pivotal Phase 3 trials; the
potential NDA submission next year; the potential for topical
roflumilast to become the standard of care for plaque psoriasis,
atopic dermatitis, scalp psoriasis, and seborrheic dermatitis; and
the potential for Arcutis to become a leading dermatology company.
These statements involve substantial known and unknown risks,
uncertainties and other factors that may cause our actual results,
levels of activity, performance or achievements to be materially
different from the information expressed or implied by these
forward-looking statements and you should not place undue reliance
on our forward-looking statements. Risks and uncertainties that may
cause our actual results to differ include risks inherent in the
clinical development process and regulatory approval process, the
timing of regulatory filings, and our ability to defend our
intellectual property. For a further description of the risks and
uncertainties applicable to our business, see the "Risk Factors"
section of our Form 10-Q filed with U.S. Securities and Exchange
Commission (SEC) on August 11, 2020, as well as any subsequent
filings with the SEC. We undertake no obligation to revise or
update information herein to reflect events or circumstances in the
future, even if new information becomes available.
Investors and Media:Heather Rowe ArmstrongVice
President, Investor Relations & Corporate
Communicationsharmstrong@arcutis.com805-418-5006, Ext. 740
Arcutis Biotherapeutics (NASDAQ:ARQT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Arcutis Biotherapeutics (NASDAQ:ARQT)
Historical Stock Chart
From Apr 2023 to Apr 2024